Company Overview of Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited researches, develops, manufactures, and markets pharmaceutical products for cardiology, nephrology, blood related, antiretroviral, gynecology, and oncology diseases in India and internationally. It offers APIs, generics, biosimilars, and differentiated formulations; and therapeutic products in the fields of hematologic/iron preparations, blood related products, cardio/anti hypertension, antibiotics, vaccines, vitamins, minerals, and nutrients. Emcure Pharmaceuticals Limited was incorporated in 1981 and is headquartered in Pune, India with operations in India, the United States, Latin America, the Middle East, and Africa.
Founded in 1981
Key Executives for Emcure Pharmaceuticals Limited
Chief Executive Officer, Managing Director, Executive Director, Member of Investor Grievance & Share Transfer Committee, Member of Remuneration Committee and Member of IPO Committee
Chief Operating Officer and Executive Director
Chief Executive Officer of Gennova Biopharmaceuticals Limited
Managing Director of Zuventus Healthcare Limited
Compensation as of Fiscal Year 2015.
Emcure Pharmaceuticals Limited Key Developments
Sagent Pharmaceuticals, Inc. Initiates Nationwide Voluntary Recall of Atracurium Besylate Injection, USP, 50mg/5mL and 100mg/10mL
Feb 23 15
Sagent Pharmaceuticals, Inc. announced the voluntary nationwide recall of two lots of Atracurium Besylate Injection, USP, 50mg/5mL single-dose vials (NDC 25021-659-05) and four lots of Atracurium Besylate Injection, USP, 100mg/10mL multi-dose vials (NDC 25021-672-10) manufactured by Emcure Pharmaceuticals Ltd. and distributed by Sagent. Sagent has initiated this voluntary recall of Atracurium Besylate Injection, USP, 50mg/5mL and 100mg/10mL to the user level due to FDA observations pertaining to aseptic and GMP practices at the manufacturer's site potentially impacting product sterility. Non-sterility of a drug administered via the intravenous route has the potential to result in infections, which could be fatal, especially in patients who are immunocompromised. Sagent has transferred the manufacture of this product to its own facility and this product manufactured at the Sagent facility will not be impacted by the recall. Sagent is not aware of any adverse patient events resulting from the use of the subject product lots. The lot numbers being recalled are VATA012, VATA015 (50mg/5mL) and VATB012, VATB013, VATB014, VATB017 (100mg/10mL) which were distributed to hospitals, wholesalers and distributors nationwide from February 2014 through February 2015. Atracurium Besylate Injection, USP, 50mg/5mL and 100mg/10mL is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation, and is supplied in single-dose and multi-dose vials. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
Sunovion Pharmaceuticals Inc. and Sunovion Pharmaceuticals Inc. File Patent Infringement Lawsuits against Emcure Pharmaceuticals Limited, Emcure Pharmaceuticals USA, Inc., and InvaGen Pharmaceuticals Inc
Jan 14 15
Sumitomo Dainippon Pharma Co. Ltd. and its Sunovion Pharmaceuticals Inc. jointly filed patent infringement lawsuits on January 14, 2015 in the U.S. District Court for the District of New Jersey against Emcure Pharmaceuticals Limited, Emcure Pharmaceuticals USA, Inc., and InvaGen Pharmaceuticals Inc. regarding their submissions of Abbreviated New Drug Applications for generic copies of Latuda® (lurasidone HCl) tablets. The lawsuits allege infringement of Sumitomo Dainippon Pharma’s U.S. Patent No. 5,532,372. The 372 Patent is licensed to Sunovion in the United States, and Sunovion has been marketing lurasidone HCl tablets in the United States under the brand name LATUDA® since its launch in February 2011. Due to the commencement of these lawsuits, the FDA approval of the ANDAs will be stayed at least until the earlier of April 28, 2018 (plus an additional six months thereafter if Sunovion is awarded a pediatric exclusivity extension) or the date of a district court decision finding the 372 Patent invalid, unenforceable, or not infringed. Should Sumitomo Dainippon Pharma and Sunovion successfully enforce the 372 Patent, ANDA approval should not occur at least until expiration of that patent on July 2, 2018 (plus an additional six months thereafter if Sunovion is awarded a pediatric exclusivity extension). Sumitomo Dainippon Pharma and Sunovion believe that their patent position for LATUDA® is strong and they are prepared to vigorously protect their patent rights.
Cipla Ltd, Strides Arcolab Ltd, Mylan Laboratories Ltd and Emcure Pharmaceuticals Ltd Sign Licensing Deals with Gilead Sciences Inc. to Sell a Low-Cost Version of its $1,000-a-Day Hepatitis C Drug Sovaldi
Sep 15 14
Cipla Ltd, Strides Arcolab Ltd, Mylan Laboratories Ltd. and Emcure Pharmaceuticals Ltd. are among six generic drug makers that are likely to sign licensing deals with Gilead Sciences Inc. to sell a low-cost version of its $1,000-a-day Hepatitis C drug Sovaldi. The licensing agreements will allow the generic drug companies to make and sell copies of the expensive pill for low- and middle-income countries at lower prices. By signing the licensing agreements with generic drug makers, Gilead is responding to criticism from governments and advocacy groups about the high pricing of the drug that has put it beyond the reach of most patients, particularly those in developing nations. The once-a-day pill used in combination with other antivirals is, however, the most effective therapy to counter Hepatitis C, which kills about 350,000 people a year globally.
Similar Private Companies By Industry
Recent Private Companies Transactions